|
|
|
|
|||||
|
|
|
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that the European Medicines Agency’s CHMP has given a positive opinion for its TRYNGOLZA.
The drug is recommended as an add-on to diet for adults with genetically confirmed familial chylomicronemia syndrome. The disease causes very high triglyceride levels and increases the risk of severe pancreatitis. Management noted that this positive opinion is a step forward towards European Commission approval, which is expected by the end of 2025.
The drug has already been approved in the United States, and the phase 3 Balance study showed that TRYNGOLZA significantly reduced triglyceride levels and acute pancreatitis events.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) develops RNA-targeted medicines for serious diseases, including neurological, cardiovascular, and rare genetic disorders.
While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 5 hours | |
| 8 hours | |
| Jul-30 | |
| Jul-30 | |
| Jul-30 | |
| Jul-30 | |
| Jul-29 | |
| Jul-25 | |
| Jul-25 | |
| Jul-23 | |
| Jul-21 | |
| Jul-16 | |
| Jul-14 | |
| Jul-10 | |
| Jul-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite